No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
ANAB250117C25000
- 0.06
- -0.07-53.85%
15min DelayClose Dec 23 16:00 ET
0.06High0.06Low
0.06Open0.13Pre Close5 Volume2.12K Open Interest25.00Strike Price30.00Turnover115.88%IV79.38%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.06Extrinsic Value100Contract SizeAmericanOptions Type0.0391Delta0.0200Gamma232.83Leverage Ratio-0.0070Theta0.0003Rho9.12Eff Leverage0.0031Vega
Intraday
- 5D
- Daily
News
Shareholders in AnaptysBio (NASDAQ:ANAB) Have Lost 60%, as Stock Drops 13% This Past Week
Truist Financial Maintains AnaptysBio(ANAB.US) With Hold Rating, Maintains Target Price $20
J.P. Morgan Maintains AnaptysBio(ANAB.US) With Buy Rating, Cuts Target Price to $36
JP Morgan Maintains Overweight on AnaptysBio, Lowers Price Target to $36
Truist Financial Maintains AnaptysBio(ANAB.US) With Hold Rating, Announces Target Price $20
Stifel Maintains AnaptysBio(ANAB.US) With Buy Rating, Cuts Target Price to $41